Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study

@article{Battistin1999AlphadihydroergocryptineIP,
  title={Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study},
  author={Leontino Battistin and Philip G. Bardin and Francesco Ferro-Milone and C. Ravenna and Vito Toso and Gianpaolo Reboldi},
  journal={Acta Neurologica Scandinavica},
  year={1999},
  volume={99}
}
Introduction ‐ A multicentre randomized double‐blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with l‐dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of α‐dihydroergocryptine (α‐DHEC) vs lisuride as an adjunct therapy to l‐dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern… 
Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study
TLDR
The results indicate that α‐dihydroergocryptine is safe and effective in improving symptoms of de novo parkinsonian patients.
Alpha-Dihydroergocryptine vs. Pramipexole as Adjunct Symptomatic Treatment of Idiopathic Parkinson’s
TLDR
DHEC and PRAM proved to be effective and safe as adjunct therapy to levodopa in idiopathic PD and have significantly improved the motor function of patients, according to the research result.
Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of changes in DAT binding with [123I]IPT SPECT
TLDR
The results of this pilot study suggest that as compared to levodopa monotherapy DEC may have beneficial effects on decline of dopamine transporter binding similar to those recently described for pramipexole.
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists
TLDR
Clinical studies on the use of dihydroergocriptine, an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease indicate that DHEC is an efficacious remedy for parkinsonian signs and symptoms.
Influence of the Dopamine Agonist &agr;-Dihydroergocryptine on the Pharmacokinetics of Levodopa in Patients with Parkinson's Disease
TLDR
The magnitude of the interaction does not suggest changing the current clinical practice of up-titrating DHEC and subsequently adapting L-Dopa to the individual needs of patients, and the effect was small but statistically significant for the area under the plasma concentration–time curve.
Preladenant: an adenosine A2A receptor antagonist for Parkinson’s disease
TLDR
Current perspectives concerning pharmacological approaches to PD, the pharmacological properties of preladenant, its efficiency and safety, as well as the results reported for parkinsonian subjects treated with this drug are reviewed.
Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
TLDR
This review focuses on and summarizes the recently reported effects of the most commonly used DA agonists either in clinical or in research studies relevant to PD treatment.
Dopamine receptor agonists in the therapy of Parkinson’s disease
TLDR
It is concluded that there is little unequivocal evidence to suggest that any of the major dopamine receptor agonists should be invariably preferred in the therapy of Parkinson’s disease; their application must be based on the needs and responses of individual patients.
Management of Parkinson's disease: An evidence‐based review
  • A. Lang, A. Lees
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2002
TLDR
A systematic review of the literature dealing with the efficacy and safety of available treatments aimed at identifying those treatments for which there is sound scientific support to justify their application and to highlight where a lack of evidence points to the need for future clinical trials.
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
TLDR
The pharmacological profile of dopamine receptor agonists suggests a possible neuroprotective effect and basic knowledge concerning the dopamine receptor stimulation which underlies their therapeutic effect is reviewed.
...
1
2
...

References

SHOWING 1-10 OF 28 REFERENCES
Multicenter study of cabergoline, a long‐acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa
TLDR
Cabergoline is an effective dopamine agonist which, because it is easy to administer, is especially useful for patients with PD and response fluctuations.
A Comparison of Bromocriptine (Parlodel®) and Levodopa-Carbidopa (Sinemet®) For Treatment of “De Novo” Parkinson's Disease Patients
TLDR
Comparison between groups did not show any significant difference for both neurological and disability assessments and the overall clinical improvement in each group was 62% (bromocriptine) and 55% (L-DOPA/carbidopa) for neurological assessment and 36% and 31% for functional disability.
Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease
TLDR
In advanced Parkinsonian patients the therapeutic efficacy of lisuride seems to be equal to that of bromocriptine as far as parkinsonian disability and fluctuations in disability are concerned.
Cabergoline in Parkinson's disease
TLDR
CBG is an efficient dopamine agonist that can provide continuous dopaminergic stimulation when taken orally once a day for motor fluctuations and dyskinesias on chronic levodopa therapy with cabergoline.
Madopar HBS in fluctuating parkinsonian patients: Two‐year treatment
TLDR
Positive results were obtained with new HBS on standard Madopar‐related psychiatric disorders and a general trend of deterioration, compared to the first 3–6 months of HBS treatment, was observed in “off” fluctuations after 1 year.
Lisuride versus bromocriptine treatment in Parkinson disease
TLDR
There was considerable variability in the optimal dose of each drug, though the clinical profile of lisuride was quite similar to that of bromocriptine, and the only significant difference was slightly better control of akinesia with bromOCriptine.
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
  • U. Rinne
  • Medicine, Psychology
    Neurology
  • 1989
TLDR
It seems advisable that treatment should begin in the early phase of the disease with a dopamine agonist such as lisuride combined with a low dose of levodopa, during a 4-year follow-up.
Long‐acting carbidopa‐levodopa in the management of moderate and advanced Parkinson's disease
TLDR
A multicenter, double-blind trial involving 202 patients with fluctuating motor response found controlled-release carbidopa-levodopa to be safe and tolerable, with improved efficacy compared with the standard formulation.
Treatment of Parkinson's disease.
...
1
2
3
...